298 related articles for article (PubMed ID: 25595737)
1. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
Grisouard J; Shimizu T; Duek A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2015 Mar; 125(13):2131-40. PubMed ID: 25595737
[TBL] [Abstract][Full Text] [Related]
2. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
Duek A; Lundberg P; Shimizu T; Grisouard J; Karow A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2014 Jun; 123(25):3943-50. PubMed ID: 24820309
[TBL] [Abstract][Full Text] [Related]
3. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
Lundberg P; Takizawa H; Kubovcakova L; Guo G; Hao-Shen H; Dirnhofer S; Orkin SH; Manz MG; Skoda RC
J Exp Med; 2014 Oct; 211(11):2213-30. PubMed ID: 25288396
[TBL] [Abstract][Full Text] [Related]
5. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
[TBL] [Abstract][Full Text] [Related]
6. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
[TBL] [Abstract][Full Text] [Related]
7. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
[TBL] [Abstract][Full Text] [Related]
8. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
[TBL] [Abstract][Full Text] [Related]
9. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
[TBL] [Abstract][Full Text] [Related]
10. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
Usart M; Stetka J; Luque Paz D; Hansen N; Kimmerlin Q; Almeida Fonseca T; Lock M; Kubovcakova L; Karjalainen R; Hao-Shen H; Börsch A; El Taher A; Schulz J; Leroux JC; Dirnhofer S; Skoda RC
Blood; 2024 Jun; 143(24):2490-2503. PubMed ID: 38493481
[TBL] [Abstract][Full Text] [Related]
11. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
12. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
Tiedt R; Hao-Shen H; Sobas MA; Looser R; Dirnhofer S; Schwaller J; Skoda RC
Blood; 2008 Apr; 111(8):3931-40. PubMed ID: 18160670
[TBL] [Abstract][Full Text] [Related]
13. Characterization of murine JAK2V617F-positive myeloproliferative disease.
Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
[TBL] [Abstract][Full Text] [Related]
14. Metformin exerts multitarget antileukemia activity in JAK2
Machado-Neto JA; Fenerich BA; Scopim-Ribeiro R; Eide CA; Coelho-Silva JL; Dechandt CRP; Fernandes JC; Rodrigues Alves APN; Scheucher PS; Simões BP; Alberici LC; de Figueiredo Pontes LL; Tognon CE; Druker BJ; Rego EM; Traina F
Cell Death Dis; 2018 Feb; 9(3):311. PubMed ID: 29472557
[TBL] [Abstract][Full Text] [Related]
15. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
16. JAK2
Zhan H; Ma Y; Lin CH; Kaushansky K
Leukemia; 2016 Dec; 30(12):2332-2341. PubMed ID: 27133820
[TBL] [Abstract][Full Text] [Related]
17. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.
Haage TR; Charakopoulos E; Bhuria V; Baldauf CK; Korthals M; Handschuh J; Müller P; Li J; Harit K; Nishanth G; Frey S; Böttcher M; Fischer KD; Dudeck J; Dudeck A; Lipka DB; Schraven B; Green AR; Müller AJ; Mougiakakos D; Fischer T
J Hematol Oncol; 2024 Jun; 17(1):43. PubMed ID: 38853260
[TBL] [Abstract][Full Text] [Related]
19. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.
Ma W; Kantarjian H; Zhang X; Wang X; Zhang Z; Yeh CH; O'Brien S; Giles F; Bruey JM; Albitar M
PLoS One; 2010 Aug; 5(8):e12165. PubMed ID: 20730051
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
